ResMed price target raised to $280 from $266 at KeyBanc

KeyBanc raised the firm’s price target on ResMed (RMD) to $280 from $266 on higher estimates and multiple, while keeping an Overweight rating on the shares. The firm believes Q2 trends were supportive of recent stock performance and sees continued upside based on its current momentum.